Sleep Duration Required to Restore Performance During Chronic Sleep Restriction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01581125|
Recruitment Status : Completed
First Posted : April 19, 2012
Last Update Posted : July 18, 2016
|Condition or disease||Intervention/treatment||Phase|
|Sleep Sleep Deprivation Insufficient Sleep Syndrome||Behavioral: Sleep:wake 1 Behavioral: Sleep:wake 2||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Sleep Duration Required to Restore Performance During Chronic Sleep Restriction|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
Experimental: Sleep:wake 2
Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
Behavioral: Sleep:wake 2
Sleep and Wake durations for arm2
Experimental: Sleep:wake 1
Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
Behavioral: Sleep:wake 1
Sleep and Wake durations for arm 1
- Psychomotor Vigilance Task (PVT) performance [ Time Frame: PVT during waking for arms 1 and 2 during the 32-day inpatient portion of the protocol ]PVT metrics are reaction time. It is measured when the participants are awake during the inpatient portion of the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01581125
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Elizabeth B Klerman, MD PhD||Brigham and Women's Hospital|